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Background
P12-2 (STRIDE; NCT01981122) is an ongoing, rando-
mized, Phase II, open-label study evaluating concurrent vs
sequential administration of the androgen receptor inhibi-
tor, enz, with the autologous cellular immunotherapy,
sip-T. The primary aim of this study is to determine if the
order of sip-T and enz administration impacts immune
responses to the immunizing antigen, PA2024, of sip-T.
Methods
Patients with asymptomatic or minimally symptomatic
mCRPC were randomized 1:1 to receive 3 sip-T infu-
sions with enz starting 2 weeks (wks) before (n=25, con-
current arm A) or 10 wks after (n=27, sequential arm B)
sip-T initiation. Antigen-specific cellular and humoral
immune responses were evaluated via interferon (IFN)-g
ELISPOT, cell proliferation, and antibody ELISA assays.
In addition, the breadth of the humoral response to
non-target antigens was also studied.
Results
T cell proliferative responses to PA2024 were signifi-
cantly elevated at all post-baseline time points (p <
0.001) and were sustained through wk 26, including a
>10-fold increase at wk 20 in both arms. Both arms
showed a significant and sustained increase in IFN-g
ELISPOT response to PA2024 and humoral responses
to PA2024 and PAP. Broadening of the humoral
responses to non-target antigens PSA, LGALS3,
LGALS8, KRAS, ERAS and KLK2 at all post-treatment
time points was observed in both arms. Cytokines indi-
cative of immune activation (including IFN-g, interleu-
kin-2, and tumor necrosis factor-a) were also elevated
in both arms, at the 2nd and 3rd sip-T infusions. Adverse
events were similar between arms.
Conclusions
Treatment of mCRPC subjects with enz administered
concurrently with or subsequent to sip-T resulted in sig-
nificant and sustained peripheral antigen-specific T cell
and humoral immune responses through wk 26. Both
treatment schedules led to similarly robust humoral anti-
gen spread sustained through wk 26. These data suggest
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